- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2051-1426
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Ipilimumab in patients with melanoma and autoimmune disease ; volume:2 ; number:1 ; day:14 ; month:10 ; year:2014 ; pages:1-4 ; date:12.2014
Journal for ImmunoTherapy of Cancer ; 2, Heft 1 (14.10.2014), 1-4, 12.2014
- Creator
-
Kyi, Chrisann
- Contributor
-
Carvajal, Richard D.
Wolchok, Jedd D.
Postow, Michael A.
SpringerLink (Online service)
- DOI
-
10.1186/s40425-014-0035-z
- URN
-
urn:nbn:de:1111-2016072656240
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:03 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kyi, Chrisann
- Carvajal, Richard D.
- Wolchok, Jedd D.
- Postow, Michael A.
- SpringerLink (Online service)
Other Objects (12)
MISIPI study: Melanoma ImmunoScore evaluation in patients treated with IPIlimumab
Development ofnivolumab/ipilimumab-associated autoimmune nephritis during steroid therapy
Neoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit disease
Analysis of T and NK cells immune response in Ipilimumab treated Melanoma patients
Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases
Acute visual loss after ipilimumab treatment for metastatic melanoma
Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian ipilimumab expanded access programme (EAP)
Melanoma antigen-specific effector T cell cytokine secretion patterns in patients treated with ipilimumab
Correlation of Baseline Tumor Burden with Clinical Outcome in Melanoma Patients Treated with Ipilimumab
A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma
Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study
Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study
MISIPI study: Melanoma ImmunoScore evaluation in patients treated with IPIlimumab
Development ofnivolumab/ipilimumab-associated autoimmune nephritis during steroid therapy
Neoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit disease
Analysis of T and NK cells immune response in Ipilimumab treated Melanoma patients
Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases
Acute visual loss after ipilimumab treatment for metastatic melanoma
Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian ipilimumab expanded access programme (EAP)
Melanoma antigen-specific effector T cell cytokine secretion patterns in patients treated with ipilimumab
Correlation of Baseline Tumor Burden with Clinical Outcome in Melanoma Patients Treated with Ipilimumab
A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma
Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study
Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study
MISIPI study: Melanoma ImmunoScore evaluation in patients treated with IPIlimumab
Development ofnivolumab/ipilimumab-associated autoimmune nephritis during steroid therapy
Neoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit disease
Analysis of T and NK cells immune response in Ipilimumab treated Melanoma patients
Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases
Acute visual loss after ipilimumab treatment for metastatic melanoma
Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian ipilimumab expanded access programme (EAP)
Melanoma antigen-specific effector T cell cytokine secretion patterns in patients treated with ipilimumab
Correlation of Baseline Tumor Burden with Clinical Outcome in Melanoma Patients Treated with Ipilimumab
A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma
Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study